today the Jacque development candidate very much call. everyone. I'd you last Thank quarterly and product our since and we've like to start greetings for progress RRP made with our INO-XXXX,
our far to, trial. project which with the so for shape productive of had As Phase have the one FDA, alluded X the for we've important this helped most been Jacque developments the design has interactions
of patients there and any challenges patients treatment be are that effect guidelines of no in RRP standardized the is intervention. time of variable studying the over candidate the for can surgical disease drug One among
questions of officially are and efficacy to our parameters device in preparing We both placebo trial, the feedback agency details before to these mind, this format and from working Phase INO-XXXX. XPSP trial. delivery some with related X start a believe the which safety clearer the conduct we With we are We additional trial the trial received provides to have controlled forward constructive assess we FDA still a including address. X Phase reflects randomized to CELLECTRA path can we to workout our
successfully device Phase two REVEALX trials, in and reminder, used REVEALX. this was X a As previously
we As to with conduct we identifying make to clinical research important appropriate preparations engaging address pivotal organization the have details, we these actively sites innovative trial. moved as under global this forward continue a
X/X and present Mau today. COSM results Meanwhile, the I'm our detailed different the Friday. demographic last included program the you Dr. shared Phase ABEA conferences Boston that trial like pleased investigator, presentation at I share more Dr. at including in with scientific safety, full Ted from to would last lead to over Mau's several at weeks, and data, medical report we've having our which immunological
a out to glance, of XX% interventions who the the a trial. pleased comparison treatment commenced the decrease following XX surgical prior Patients year the of intervention a surgeries This year of the really including experienced in in our the prior patients in baseline. X involved that after slide that during of were in at for patients impact patients to I'm year. year, in had treatment the median or shows, surgical XX required to on XX% XXXX number decrease surgeries versus or that no experienced three summarize year
window, the a efficacy performed As reminder, day zero, was against counted following endpoint. surgery during the any including dosing
reduction as RRP a that expressed important surgeries is them a have meaningful patients reminder, and difference. well to is that and the their a physicians even of outcome as surgery reduction one in most a As advocates,
In demographics The with of prior was XX the an XX. a in of involved patients years to with of surgeries range age dosing XX median to to number terms year X trial, median X range was the age of of the the X. in
is that our as slide INO-XXXX shows An safety XXXX's in of in important and overall Phase tolerability X/X trial. on safety, behaved DNA general favorable medicines This expected front profile. hallmark and
events participated related INO-XXXX. leading four emergent unrelated can in experienced X. the observed most reported adverse emergent injection being generally either administration, AEs treatment pain. X to were trial here were X to AE, You serious but patients related emergent grade, adverse site to the all frequently all see treatments. were received reported pain trial the trial, who were Two were most events grade XX grade subjects deemed a treatment again, during but AEs and Treatment no the treatment which both low in or procedural of There to the were INO-XXXX. discontinuation deemed treatment emergent none of
voice scores like scores subjective I'd The distribution, the from assessment therapy measures assessment course to data Next, as patients, of system disease clinical essentially of include Staging individual's highlight both frequently the well patients. which There for RRP RRP is as adult of related symptom by time. is and the staging assessed most data with that the an staging scores. combination disease clinical supporting a over anatomic response assessing functional burden. to correlates anatomic reported the of as the an in well also burden parameters of quality assessment total the life assessment
the in for assessment see As based the data total combined the on there improvements score in were all you on patients the the trial. can slide,
to looks our reminder that patient, call. actually of a a a what quarterly we for last like showed As slide share at I'd like
of For from patients me, of disease it benefit could this clinical terrible it's how powerful provide relief. INO-XXXX a and illustration the potentially suffering
and indicating was CDX weeks clearing response both saw HPV-XX, at type infected highlights to and final cellular treatment INO-XXXX and Next, response. on in activated Treatment this T-cells. some we I'd observed were memory believe T-cell share in CDX cellular HPV responses cells. of both be activated immune We response lytic week-XX, cytotoxic this which responses may induced CDX against trial. cellular a XX inducing the after persistent HPV-X with important also like T-cell
specific effect Additional important CDX analyses for improve of outcomes, as we phenotypes the will clinical look and possible studying are treatment the This be repeat requirement clinical relationship also to and a ongoing further to between at and determine dosing. outcomes. likely ways CDX duration including
data electroporation suggests I'd highlight with summary, INO-XXXX his conclusions the In well that profile. administered that during favorable a intramuscular safety noted the Dr. tolerated was presentation. to with made Investigators Mau like
in adult with RRP it together further also benefit to appears clinical addition, patients INO-XXXX trial. In supports investigation provide to X of a Phase and
The Committee the opinion application designation recently regulatory for received for will for is decision, EU drug European Orphan for Products orphan that final to Commission and positive competition opinion of INO-XXXX. Moving this as fees and Medicinal month. approved. from the market next designation now a slide, European on later we Orphan XX our provide such years their Inovio expected from the benefits would once which activities protection make important reduced in review
considerable the with a to of Furthermore, provide we We to both also on and believe to the European therefore pediatric and in forward could burden Union population pediatric INO-XXXX these places development. recognize the U.S. plan clinical approach the patients. RRP benefit proposal how move
At once Washington Conference again the has their International the reminded of I on lives. was Papillomavirus in I attended, that caregivers' RRP recent DC patients impact and considerable
we an As day in patients world. move single we keeping to mind organization, for work as that around INO-XXXX are the forward every
we conducted that did not HPV on squamous results epithelial call, from significance shared some our patients At positive focusing the the On in trial HSIL. high lesions that with wanted biomarker updates or our our statistical to grade product announced last on franchise, was our which we achieve on provide Staying study, cervical earnings I REVEALX time, candidate population. also VGX-XXXX, in HSIL.
statistical population. did study all-comers achieve in the the However, significance
saw Looking by studies, the collected related where VGX-XXXX remain data XX% group across REVEALX the of group. viral X% versus viral of data totality in the we including in treated in the placebo we in clearance encouraged HPV clearance for we've diseases, various
data, on To get better highlighting a two handle biomarker areas. been have results we the main analyzing the
stage as with of not age, respond why focus some site and status. with disease, location, a biomarker other did treatment at a subjects clinical looking characteristics determination of of to clinical such infection types, HPV positive smoking Firstly,
Secondly, patients who we to why clinical are response exhibited a were looking not positive. understand some biomarker
investigate the in to For detail. plan this, dataset more RNA micro we
of in going indication. to care for for standard able XXXX. biomarker loop electrosurgical able the a demonstrate excision you standpoint a quarter procedure, well-established regulatory competitive similar the this third is cervical U.S. in a to important benefit risk that in expect to profile Being with be from analysis analysis future We must compete into LEEP VGX-XXXX further be HSIL. discussions as is to of provide vital This or insights the
VGX-XXXX, other has in also studied anal however, including been indications HSIL.
label, trial announced and XXXX XX evidence single for had in our participants HSIL arm, of As which in of out X open saw a at no anal positive results that or we Phase December XX HSIL XX% of week-XX. reminder, HPV-XX HPV-XX we
In Inovio externally potential the is positive addition, examining consortium study HSIL. in ongoing run by sponsored HIV malignancy individuals with supporting an anal of AIDS the VGX-XXXX
anal progress Anal in XX% HSIL infections, over and is HPV-XX is HPV for account may HPV-XX left HPV-XX cancer. cancers untreated to caused by and detected HPV-XX mostly of and and XX% the XXX,XXX if anal European anal million HPV figures prevalence estimated in of In range U.S. of HPV-XX approximately HPV-XX from prevalence the HSIL to genotypes related detected. estimates with alone Union. X.X and similar
NIH to the proactive study is of common and treatment a showed funded positive cancer. practice options. of patients progression for been research greater in anal or the is prevention anal results HSIL paid cancer now NCI Recent attention HSIL, HSIL that clinical historically from being outcomes treatment anal HIV ANCHOR in to has waiting superior watchful While
of treatment surgical. condition present, radiofrequency resections, ablation, At therapy. this or is That laser includes usually
However, met infection XX% and that treatment. up year rates believe with HPV which This need recurrent clear us be high is therapeutic is one HSIL treatment the disease candidate to potentially like a most currently leads after a the common significant anal VGX-XXXX. does underlying could ablation with unmet not to are
the treat I data anal from cause determine of phase HSIL to FDA the cases. our European as confidence viral indication. regulators The to of cervical started we discussions three the majority well mentioned key this with path leaders for additional have both on underlying data the forward clearance and of Based feedback from positive potential earlier opinion our two the HSIL in Phase XXXX regarding Union as X provide studies, the
to vaccine like Now, I virus. the INO-XXXX, Zaire booster targeting switch gears to DNA a Ebola would
Dr. dose XXrd of and immunological compared immunogenic that of data along a Huttner, showed lead of recently, well and mentioned PhaseXb to the trial INO-XXXX for intradermal investigator tolerated primed Diseases. the Angela Jacque Infectious As at with healthy electroporation single ERVEBO. cohort placebo trial of The Congress Clinical and Microbiology new safety presented volunteers a INO-XXXX, was in European with
time both rising As you demonstrated antibody antibody can point binding XXX% peaking significantly at the profile. after see slide, rose Likewise, and neutralizing measured similar in neutralizing boost on subjects this at a titers titers binding a of significantly titers with each week-two. antibody
see a noteworthy On of engagement this can next slide, T-cells. you
boost. Specifically, and interferon-gamma observed looking production of an we T-cells increased cytokines ThX the positive CDX at ILXX TNFα INO-XXXX CDX following from
Given booster is SARS-CoV-X, strong cellular may the aiding disease response for cellular in the the that a in increasing against attention in of on profile believe infectious in such durability the we to Ebola. protection immunity protecting humeral a having and its diseases as a addition play value potential potential response role severe for
most protection disease CDX of was dose production predominantly memory extend the strain positive in affect seem Finally, Ebola. phenotyping memory booster an and T-cells, the and persistent protection central suggests Ebola that has potential against the suggests The memory T-cells a threat presented not positive indicative the future tool likely against prevention, data cytokine INO-XXXX CDX marker generated from that Ebola important waning. to a be be Zaire could does virus of to
regulatory set we end. by with in pathway agencies proposed increases After past up next a consistently a and position see, share on continent potential outbreaks to to believe you few a the world since XXXX, pop and globalized the alignment borders. development these goal we have are outbreaks can consultation As across shown, external have as now year jump have steps the to African continued for years our for only experts, with
ultimately of an with Research spearheaded medicines. human Agency by advance by example how The Advanced of or GuardRX, health, amplify Inovio's latest the sponsored shows funded DARPA. platform, power the improve opportunities and INO-XXXX is that excellent and work explore Geneva real Hospitals, partnerships Projects partnerships by potential University DNA Defense providing innovate, U.S. could collaboration indications of to our This the can
the externally as Diseases. HSIL We two Institute for malignancy candidates pipeline X HIV Phase trial the X mentioned, of by sponsored I National the development, previously as AIDS by consortium the sponsored programs in at several trials various stages including Allergy that positive Phase have other HIV of well and sponsored in anal in Infectious
DARPA partners also vision. the DNA forward Indiana funded antibodies. with made updates continue additional align to they a and strategic specific collaboration develop our to We opportunities that have with available to We look of Institute, Wistar from explore sharing anti Pennsylvania, our are and monoclonal AstraZeneca SARS-CoV-X as or encoded partnership University University, to we'll us, DMAbs
over that, Peter? for call our I'll quarter Peter to the first With Kies XXXX summary. now financial our CFO, turn
